Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51


Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma.

Ambady P, Szidonya L, Firkins J, James J, Johansson K, White T, Jezierski C, Doolittle ND, Neuwelt EA.

Leuk Lymphoma. 2019 Feb;60(2):515-518. doi: 10.1080/10428194.2018.1480771. Epub 2018 Jul 22. No abstract available.


Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency.

Dósa E, Heltai K, Radovits T, Molnár G, Kapocsi J, Merkely B, Fu R, Doolittle ND, Tóth GB, Urdang Z, Neuwelt EA.

Fluids Barriers CNS. 2017 Oct 3;14(1):26. doi: 10.1186/s12987-017-0075-0.


Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.

Ambady P, Fu R, Netto JP, Kersch C, Firkins J, Doolittle ND, Neuwelt EA.

Fluids Barriers CNS. 2017 Jun 2;14(1):16. doi: 10.1186/s12987-017-0064-3.


Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, Dosa E, Finn JP, Gahramanov S, Harisinghani M, Macdougall I, Neuwelt A, Vasanawala SS, Ambady P, Barajas R, Cetas JS, Ciporen J, DeLoughery TJ, Doolittle ND, Fu R, Grinstead J, Guimaraes AR, Hamilton BE, Li X, McConnell HL, Muldoon LL, Nesbit G, Netto JP, Petterson D, Rooney WD, Schwartz D, Szidonya L, Neuwelt EA.

Kidney Int. 2017 Jul;92(1):47-66. doi: 10.1016/j.kint.2016.12.037. Epub 2017 Apr 20. Review.


Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.

Doolittle ND, Muldoon LL, Culp AY, Neuwelt EA.

Adv Pharmacol. 2014;71:203-43. doi: 10.1016/bs.apha.2014.06.002. Epub 2014 Aug 22. Review.


Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.

Doolittle ND, Dósa E, Fu R, Muldoon LL, Maron LM, Lubow MA, Tyson RM, Lacy CA, Kraemer DF, Butler RW, Neuwelt EA.

J Clin Oncol. 2013 Nov 1;31(31):4026-7. doi: 10.1200/JCO.2013.52.7747. Epub 2013 Oct 7. No abstract available.


Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.

Farrell BT, Hamilton BE, Dósa E, Rimely E, Nasseri M, Gahramanov S, Lacy CA, Frenkel EP, Doolittle ND, Jacobs PM, Neuwelt EA.

Neurology. 2013 Jul 16;81(3):256-63. doi: 10.1212/WNL.0b013e31829bfd8f. Epub 2013 Jun 14.


Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA.

Neurology. 2013 Jul 2;81(1):84-92. doi: 10.1212/WNL.0b013e318297eeba. Epub 2013 May 17.


Immunologic privilege in the central nervous system and the blood-brain barrier.

Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, Prat A, Scarpa M, Smeyne RJ, Drewes LR, Neuwelt EA.

J Cereb Blood Flow Metab. 2013 Jan;33(1):13-21. doi: 10.1038/jcbfm.2012.153. Epub 2012 Oct 17. Review.


Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

Muldoon LL, Lewin SJ, Dósa E, Kraemer DF, Pagel MA, Doolittle ND, Neuwelt EA.

Clin Cancer Res. 2011 Apr 15;17(8):2207-15. doi: 10.1158/1078-0432.CCR-10-2923. Epub 2011 Mar 8.


Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin SE, Guerrera M, Shah S, Ghesquieres H, Silver M, Betensky RA, Batchelor T.

Clin Cancer Res. 2011 Jan 15;17(2):346-52. doi: 10.1158/1078-0432.CCR-10-1161. Epub 2011 Jan 11.


Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, Neuwelt EA.

Neurosurgery. 2010 Jan;66(1):48-58; discussion 58. doi: 10.1227/01. NEU.0000363152.37594. F7.


Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.

Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, Stevens G, McGregor J, Jahnke K, Lacy CA, Hedrick NA, Shalom E, Ference S, Bell S, Sorenson L, Tyson RM, Haluska M, Neuwelt EA.

J Clin Oncol. 2009 Jul 20;27(21):3503-9. doi: 10.1200/JCO.2008.19.3789. Epub 2009 May 18.


N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.

Stenstrom DA, Muldoon LL, Armijo-Medina H, Watnick S, Doolittle ND, Kaufman JA, Peterson DR, Bubalo J, Neuwelt EA.

J Vasc Interv Radiol. 2008 Mar;19(3):309-18. doi: 10.1016/j.jvir.2007.11.003. Review.


Brain metastases in hematologic malignancies.

Doolittle ND.

Cancer Treat Res. 2007;136:169-83. Review. No abstract available.


Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.

Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, Muldoon LL, Neuwelt EA.

Cancer. 2008 Feb 1;112(3):581-8.


Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report.

Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E.

Blood. 2008 Feb 1;111(3):1085-93. Epub 2007 Oct 25.


Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models.

Dickey DT, Muldoon LL, Doolittle ND, Peterson DR, Kraemer DF, Neuwelt EA.

Cancer Chemother Pharmacol. 2008 Jul;62(2):235-41. Epub 2007 Oct 2.


Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay JY, Ferreri AJ, Omuro AM, Thiel E, Abrey LE.

Ann Oncol. 2007 Nov;18(11):1851-5. Epub 2007 Sep 5.


Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.

Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA.

Leuk Lymphoma. 2007 Sep;48(9):1712-20.


Implications of the blood-brain barrier in primary central nervous system lymphoma.

Jahnke K, Doolittle ND, Muldoon LL, Neuwelt EA.

Neurosurg Focus. 2006 Nov 15;21(5):E11. Review.


Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.

Doolittle ND, Peereboom DM, Christoforidis GA, Hall WA, Palmieri D, Brock PR, Campbell KC, Dickey DT, Muldoon LL, O'Neill BP, Peterson DR, Pollock B, Soussain C, Smith Q, Tyson RM, Neuwelt EA.

J Neurooncol. 2007 Jan;81(1):81-91. Epub 2006 Jul 21.


Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.

Muldoon LL, Tratnyek PG, Jacobs PM, Doolittle ND, Christoforidis GA, Frank JA, Lindau M, Lockman PR, Manninger SP, Qiang Y, Spence AM, Stupp SI, Zhang M, Neuwelt EA.

AJNR Am J Neuroradiol. 2006 Mar;27(3):715-21.


Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.

Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA.

J Neurooncol. 2006 May;77(3):279-84. Epub 2005 Nov 29.


Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.

Neuwelt EA, Gilmer-Knight K, Lacy C, Nicholson HS, Kraemer DF, Doolittle ND, Hornig GW, Muldoon LL.

Pediatr Blood Cancer. 2006 Aug;47(2):174-82.


New treatment approaches in primary central nervous system lymphoma.

Soussain C, Hoang-Xuan K, Doolittle ND.

Hematol Oncol Clin North Am. 2005 Aug;19(4):719-28, vii. Review.


Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery.

Neuwelt EA, Guastadisegni PE, Várallyay P, Doolittle ND.

AJNR Am J Neuroradiol. 2005 Feb;26(2):258-65.


New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.

Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin SD, Smith Q, Stevens GH, Neuwelt EA.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):421-8.


State of the science in brain tumor classification.

Doolittle ND.

Semin Oncol Nurs. 2004 Nov;20(4):224-30. Review.


Current status and future of relapsed primary central nervous system lymphoma (PCNSL).

Tyson RM, Siegal T, Doolittle ND, Lacy C, Kraemer DF, Neutwelt EA.

Leuk Lymphoma. 2003 Apr;44(4):627-33.


Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.

Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J.

Ophthalmology. 2002 Sep;109(9):1709-16.


Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.

Doolittle ND, Abrey LE, Ferrari N, Hall WA, Laws ER, McLendon RE, Muldoon LL, Peereboom D, Peterson DR, Reynolds CP, Senter P, Neuwelt EA.

Clin Cancer Res. 2002 Jun;8(6):1702-9.


Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV Cytoxan chemotherapy for progressive optic-hypothalamic gliomas in young children.

Osztie E, Várallyay P, Doolittle ND, Lacy C, Jones G, Nickolson HS, Neuwelt EA.

AJNR Am J Neuroradiol. 2001 May;22(5):818-23.


Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival.

Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA.

Neurosurgery. 2001 May;48(5):1033-40; discussion 1040-1.


Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.

Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA.

Neuro Oncol. 2001 Jan;3(1):46-54. doi: 10.1093/neuonc/3.1.46.


Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors.

Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, Kraemer DF, Heinrich MC, Henry JA, Neuwelt EA.

Clin Cancer Res. 2001 Mar;7(3):493-500.


Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.

Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, Egorin MJ, Neuwelt EA.

Clin Cancer Res. 2000 Jan;6(1):309-15.


Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors.

Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA.

Cancer. 2000 Feb 1;88(3):637-47.


Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA.

Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1.


Cerebrovascular Biology and the various neural barriers: challenges and future directions.

Neuwelt EA, Abbott NJ, Drewes L, Smith QR, Couraud PO, Chiocca EA, Audus KL, Greig NH, Doolittle ND.

Neurosurgery. 1999 Mar;44(3):604-8; discussion 608-9.


First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate.

Neuwelt EA, Brummett RE, Doolittle ND, Muldoon LL, Kroll RA, Pagel MA, Dojan R, Church V, Remsen LG, Bubalo JS.

J Pharmacol Exp Ther. 1998 Jul;286(1):77-84.


Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program.

Doolittle ND, Petrillo A, Bell S, Cummings P, Eriksen S.

J Neurosci Nurs. 1998 Apr;30(2):81-90. Review.


The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.

Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA.

Cancer J Sci Am. 1998 Mar-Apr;4(2):110-24.


A study of the psychosocial characteristics of patients in a geriatric rehabilitation unit in Israel.

Nir Z, Wallhagen MI, Doolittle ND, Galinsky D.

Rehabil Nurs. 1997 May-Jun;22(3):143-51; quiz 168. Review.


The experience of recovery following lacunar stroke.

Doolittle ND.

Rehabil Nurs. 1992 May-Jun;17(3):122-5.


Clinical ethnography of lacunar stroke: implications for acute care.

Doolittle ND.

J Neurosci Nurs. 1991 Aug;23(4):235-40.


Advances in the neurosciences and implications for nursing care.

Doolittle ND.

J Neurosci Nurs. 1991 Aug;23(4):207-10. Review.


Supplemental Content

Loading ...
Support Center